Vildagliptin
Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors
Sold as Jalra · Galvus · Xiliarx · Eucreas · Zomarist
- Drug class
- Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors
- Availability
- See label
- Markets covered
- 2
- Products on record
- 53
Overview
Vildagliptin is an active pharmaceutical ingredient in the Dipeptidyl Peptidase 4 (Dpp-4) Inhibitors group (A10BH). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 46 | May 22, 2026 |
| EU European Union | EMA | 7 | January 5, 2026 |
GBUnited Kingdom· MHRA
46 products
Uses
Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:
As monotherapy • in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance. As dual oral therapy in combination with • metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin, • a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance, • a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione is appropriate.
As triple oral therapy in combination with • a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control. Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and exercise plus a stable dose of insulin do not provide adequate glycaemic control.
EUEuropean Union· EMA
7 products
Uses
Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus: • as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.
1 for available data on different combinations).
How to take
Sources & citations
- [1]MHRA (UK) · PL068310321 · revised June 6, 2025
- [2]European Medicines Agency · EMEA/H/C/001048 · revised January 5, 2026
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.